Taimei Technology, an AI-powered drug clinical development platform company, and C&R Research, a Contract Research Organisation (CRO) in South Korea, signed an enterprise-level strategic partnership agreement to officially launch the development of an AI-based clinical trial operations system.
Zhao Lu, chairman of Taimei Technology, said: “This partnership represents an important opportunity to bring the AI clinical operations experience we have accumulated in global markets into South Korea. We look forward to collaborating with more Korean ecosystem partners to continuously drive the intelligent transformation of clinical trials.”
Building AI-powered clinical trial innovation
The partnership aims to automate and enhance trial design and operational workflows by integrating Taimei Technology’s digital infrastructure and AI agents into C&R Research’s existing clinical trial processes.
The adoption of EDC + iDM Agent focuses on data management, while intelligent data capture and governance, AI-driven eCRF generation, and automated test case creation aim to boost productivity and quality in clinical research.
The two companies plan to integrate AI-driven operational models with Korea’s CRO-centric clinical trial execution system to build a more efficient and intelligent clinical research framework.
Moon Tae Yoon, CEO of C&R Research, said: “As clinical trials become increasingly complex, AI-based data management and operational automation are emerging as essential competitive factors. Through this partnership, we will build a more efficient and innovative clinical execution system.”
